{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:47:59Z","timestamp":1790023679759,"version":"4.0.1"},"reference-count":159,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The incidence of melanoma and non-melanoma skin cancers (NMSCs) is increasing worldwide. While NMSCs are more common, melanoma remains the most challenging because of its higher aggressiveness. Although the use of sunscreens is key in high-risk populations, it provides limited protection, which highlights the need for alternative solutions. In this review, we discuss current evidence on chemopreventive therapies, as well as their efficacy and adverse events, including immunocompetent and immunosuppressed patients. Acitretin, nicotinamide, 5-fluorouracil, and photodynamic therapy have shown overall promising results in actinic keratosis and squamous cell carcinoma. Nevertheless, more research is needed to establish their efficacy, particularly in melanoma, Merkel cell carcinoma, and cutaneous lymphoma, due to their higher mortality rates.<\/jats:p>","DOI":"10.3390\/cancers18030436","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:08:57Z","timestamp":1769681337000},"page":"436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemoprevention in Skin Cancer: What Advice?"],"prefix":"10.3390","volume":"18","author":[{"given":"Ariadna","family":"Ortiz-Brugu\u00e9s","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-7856","authenticated-orcid":false,"given":"Carmen","family":"Orte Cano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-1083","authenticated-orcid":false,"given":"Lluis","family":"Corbella","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-9680","authenticated-orcid":false,"given":"Francesc","family":"Alamon-Reig","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Mart\u00ed-Mart\u00ed","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ayguasanosa-Avila","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hern\u00e1ndez-Santacana","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Giavedoni","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8820","authenticated-orcid":false,"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaad.2021.03.109","article-title":"United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019","volume":"85","author":"Aggarwal","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1038\/s41598-021-83502-8","article-title":"The incidence and clinical analysis of non-melanoma skin cancer","volume":"11","author":"Lange","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115152","DOI":"10.1016\/j.ejca.2024.115152","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics\u2014Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.18195","article-title":"Prevention and screening of melanoma in Europe: 20 years of the Euromelanoma campaign","volume":"36","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2011.10.012","article-title":"Chemoprevention\u2014History and general principles","volume":"25","author":"Wu","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rembielak, A., and Tagliaferri, L. (2023). Chemoprevention and Photoprotection in Non-Melanoma Skin Neoplasm. Non-Melanoma Skin Cancer\u2014Essentials for Oncologists, CRC Press. [1st ed.].","DOI":"10.1201\/9781003226017"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/bjd\/ljaf221","article-title":"Acitretin chemoprevention in patients with nonmelanoma skin cancer with chronic haematopoietic disease: Findings from three independent databases","volume":"193","author":"Sia","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ramchatesingh, B., Mart\u00ednez Villarreal, A., Arcuri, D., Lagac\u00e9, F., Setah, S.A., Touma, F., Al-Badarin, F., and Litvinov, I.V. (2022). The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012622"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo- controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_11","first-page":"CD005414","article-title":"Interventions for preventing non-melanoma skin cancers in high-risk groups","volume":"2015","author":"Somchand","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1111\/ajd.13821","article-title":"A long-term cohort study of acitretin for prevention of keratinocyte carcinoma in solid organ transplant recipients","volume":"63","author":"Allnutt","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000515496","article-title":"Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients","volume":"238","author":"Hodak","year":"2022","journal-title":"Dermatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaad.2023.11.034","article-title":"Effectiveness of acitretin for skin cancer prevention in immunosuppressed and nonimmunosuppressed patients: A retrospective cohort study","volume":"90","author":"Bhullar","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.26374","article-title":"Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)","volume":"118","author":"Kadakia","year":"2012","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/14656566.9.8.1363","article-title":"Systemic retinoids in chemoprevention of non-melanoma skin cancer","volume":"9","author":"Lens","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/09546634.2012.746634","article-title":"Retinoids in the chemoprevention of non-melanoma skin cancers: Why, when and how","volume":"24","author":"Bettoli","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"ref_19","first-page":"957","article-title":"Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial","volume":"6","author":"Levine","year":"1997","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/84.5.328","article-title":"Long-Term Therapy with Low-Dose Isotretinoin for Prevention of Basal Cell Carcinoma: A Multicenter Clinical Trial","volume":"84","author":"Tangrea","year":"1992","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_21","first-page":"753","article-title":"Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients","volume":"9","author":"Marquez","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamadermatol.2019.1937","article-title":"Association of Vitamin A Intake with Cutaneous Squamous Cell Carcinoma Risk in the United States","volume":"155","author":"Kim","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-03-0188","article-title":"Safety and Efficacy of Dose-Intensive Oral Vitamin A in Subjects with Sun-Damaged Skin","volume":"10","author":"Alberts","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.287.1.47","article-title":"Vitamin A Intake and Hip Fractures Among Postmenopausal Women","volume":"287","author":"Feskanich","year":"2002","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fania, L., Mazzanti, C., Campione, E., Candi, E., Abeni, D., and Dellambra, E. (2019). Role of nicotinamide in genomic stability and skin cancer chemoprevention. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235946"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e14892","DOI":"10.1111\/dth.14892","article-title":"Oral nicotinamide: The role in skin cancer chemoprevention","volume":"34","author":"Giacalone","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nikas, I.P., Paschou, S.A., and Ryu, H.S. (2020). The Role of Nicotinamide in Cancer Chemoprevention and Therapy. Biomolecules, 10.","DOI":"10.3390\/biom10030477"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ijd.15442","article-title":"Is the first-line systemic chemoprevention of nonmelanoma skin cancer nicotinamide or acitretin?","volume":"60","author":"Hoegler","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/jid.2011.459","article-title":"Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials","volume":"132","author":"Surjana","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1684\/ejd.2017.3025","article-title":"Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: A case-control study","volume":"27","author":"Drago","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc1514791","article-title":"Nicotinamide for Skin-Cancer Chemoprevention","volume":"374","author":"Yi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients","volume":"388","author":"Allen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113251","DOI":"10.1016\/j.ejca.2023.113251","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention\u2014Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jamadermatol.2025.3238","article-title":"Nicotinamide for Skin Cancer Chemoprevention","volume":"161","author":"Breglio","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00403-025-04296-7","article-title":"Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients","volume":"317","author":"Hwang","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.32.10.1122","article-title":"Interactions between primidone, carbamazepine, and nicotinamide","volume":"32","author":"Bourgeois","year":"1982","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14082","DOI":"10.1111\/dth.14082","article-title":"Inflammatory actinic keratosis following capecitabine therapy","volume":"33","author":"Antoniolli","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jamadermatol.2020.2327","article-title":"Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review","volume":"156","author":"Schauder","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1399-0012.2010.01348.x","article-title":"Capecitabine for skin cancer prevention in solid organ transplant recipients","volume":"25","author":"Jirakulaporn","year":"2011","journal-title":"Clin. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/dsu.12049","article-title":"Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients","volume":"39","author":"Endrizzi","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s12276-020-0412-2","article-title":"New insights into the functions of Cox-2 in skin and esophageal malignancies","volume":"52","author":"Moon","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., Borthakur, A., Afroz, S., Arthur, S., and Sundaram, U. (2021). Unique Regulation of Intestinal Villus Epithelial Cl\u2212\/HCO3\u2212 Exchange by Cyclooxygenase Pathway Metabolites of Arachidonic Acid in a Mouse Model of Spontaneous Ileitis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084171"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1940-6207.CAPR-09-0200","article-title":"Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+\/\u2212 humans and mice","volume":"3","author":"Tang","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, B., Liang, X., Ye, L., and Wang, Y. (2014). No chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancer: Evidence from meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096887"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/jid.2014.531","article-title":"Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can Prevent Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"135","author":"Muranushi","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-21-0244","article-title":"Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial","volume":"15","author":"Yan","year":"2022","journal-title":"Cancer Prev. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1038\/s41598-018-23439-7","article-title":"Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation","volume":"8","author":"Ikeya","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/erm.2013.3","article-title":"Polyamines and cancer: Implications for chemotherapy and chemoprevention","volume":"15","author":"Nowotarski","year":"2013","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1940-6207.CAPR-09-0096","article-title":"A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of DFMO in subjects with previous history of skin cancer","volume":"3","author":"Bailey","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1940-6207.CAPR-12-0233","article-title":"A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity","volume":"12","author":"Kreul","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/lary.30231","article-title":"Ototoxicity of Long-Term \u03b1-Difluoromethylornithine for Skin Cancer Prevention","volume":"133","author":"Chow","year":"2023","journal-title":"Laryngoscope"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/12034754241302818","article-title":"Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review","volume":"29","author":"Koulmi","year":"2025","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kim, S., Woo, Y.R., Cho, S.H., Lee, J.D., and Kim, H.S. (2024). Clinical Efficacy of 5-Fluorouracil and Bleomycin in Dermatology. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020335"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jdv.19897","article-title":"European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes)","volume":"38","author":"Kandolf","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: Natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_60","first-page":"1218","article-title":"Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared with 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis","volume":"15","author":"Dohil","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_61","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis","volume":"70","author":"Jorizzo","year":"2002","journal-title":"Cutis"},{"key":"ref_62","first-page":"22","article-title":"Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks","volume":"70","author":"Weiss","year":"2002","journal-title":"Cutis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","article-title":"Efficacy and Safety of 5-Fluorouracil 0.5%\/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial","volume":"7","author":"Stockfleth","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36849\/JDD.6632","article-title":"Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review","volume":"21","author":"Mohney","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13555-021-00668-9","article-title":"Intensity of Local Skin Reactions During 5-Fluorouracil Treatment Related to the Number of Actinic Keratosis Lesions: A Post Hoc, Exploratory Analysis","volume":"12","author":"Stockfleth","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archderm.139.10.1325","article-title":"Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo","volume":"139","author":"Urosevic","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_67","first-page":"71","article-title":"Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression","volume":"13","author":"Kono","year":"1994","journal-title":"Lymphokine Cytokine Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ijd.13235","article-title":"Imiquimod in dermatology: An overview","volume":"55","author":"Hanna","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bernal Masferrer, L., Gracia Caza\u00f1a, T., Bernad Alonso, I., \u00c1lvarez-Salafranca, M., Almenara Blasco, M., Gallego Rentero, M., Juarranz de la Fuente, \u00c1., and Gilaberte, Y. (2024). Topical Immunotherapy for Actinic Keratosis and Field Cancerization. Cancers, 16.","DOI":"10.3390\/cancers16061133"},{"key":"ref_70","first-page":"1099","article-title":"Treatment of actinic keratosis: A systematic review","volume":"315","author":"Worley","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Vegter, S., and Tolley, K. (2014). A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096829"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Arcuri, D., Ramchatesingh, B., Lagac\u00e9, F., Iannattone, L., Netchiporouk, E., Lefran\u00e7ois, P., and Litvinov, I.V. (2023). Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054989"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s13555-023-00978-0","article-title":"Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management","volume":"13","author":"Zhang","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/039463201002300201","article-title":"Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients","volume":"23","author":"Trakatelli","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/jvc2.376","article-title":"Rechallenge and retreatment with topical imiquimod 5% in transplant recipients: A multicenter experience on actinic keratoses and basal cell carcinomas","volume":"3","author":"Fava","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","article-title":"Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients","volume":"157","author":"Ulrich","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archderm.141.8.985","article-title":"Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients","volume":"141","author":"Brown","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","article-title":"A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions","volume":"23","author":"Catapano","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized Trial of Four Treatment Approaches for Actinic Keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14740338.2021.1915280","article-title":"Safety of topical interventions for the treatment of actinic keratosis","volume":"20","author":"Koch","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1468-3083.2009.03399.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses","volume":"24","author":"Dirschka","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.23736\/S2784-8671.21.07111-5","article-title":"Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: An integrated low-intensity intervention program versus standard-of-care","volume":"157","author":"Perino","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1684\/ejd.2010.1010","article-title":"Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses","volume":"20","author":"Ulrich","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Piaserico, S., Mazzetto, R., Sartor, E., and Bortoletti, C. (2022). Combination-Based Strategies for the Treatment of Actinic Keratoses with Photodynamic Therapy: An Evidence-Based Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081726"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-025-02615-6","article-title":"Ingenol mebutate in cancer therapy: Mechanisms, clinical applications and future directions","volume":"42","author":"Shafombabi","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol Mebutate Gel for Actinic Keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_88","unstructured":"European Medicines Agency (2026, January 18). Picato (Ingenol Mebutate): Risks of Skin Cancer Outweigh Benefits. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/picato."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1586\/era.10.154","article-title":"Recent advances in the prevention and treatment of skin cancer using photodynamic therapy","volume":"10","author":"Zhao","year":"2010","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clindermatol.2005.10.027","article-title":"Laser-mediated photodynamic therapy","volume":"24","year":"2006","journal-title":"Clin. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-023-00888-1","article-title":"Advances in Photodynamic Therapy for the Treatment of Actinic Keratosis and Nonmelanoma Skin Cancer: A Narrative Review","volume":"13","author":"Farberg","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Correia, J.H., Rodrigues, J.A., Pimenta, S., Dong, T., and Yang, Z. (2021). Photodynamic therapy review: Principles, photosensitizers, applications, and future directions. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091332"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2133.2011.10270.x","article-title":"Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers","volume":"165","author":"Bagazgoitia","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.16044","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: Emerging indications\u2014Field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"34","author":"Morton","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wulf, H.C., Al-chaer, R.N., Glud, M., Philipsen, P.A., and Lerche, C.M. (2021). A skin cancer prophylaxis study in hairless mice using methylene blue, riboflavin, and methyl aminolevulinate as photosensitizing agents in photodynamic therapy. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050433"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2133.2009.09492.x","article-title":"Skin cancer: Preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study","volume":"162","author":"Apalla","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"452","DOI":"10.36849\/JDD.2020.4930","article-title":"A Randomized Trial of Broad Area ALA\u2013PDT for Field Cancerization Mitigation in High-Risk Patients","volume":"19","author":"Piacquadio","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjd.17148","article-title":"Local interventions for actinic keratosis in organ transplant recipients: A systematic review","volume":"180","author":"Heppt","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.TP.0000107284.04969.5C","article-title":"Topical photodynamic therapy in the treatment of actinic keratoses and Bowen\u2019s disease in transplant recipients","volume":"77","author":"Dragieva","year":"2004","journal-title":"Transplantation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00015550510042868","article-title":"Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients","volume":"86","author":"Wulf","year":"2006","journal-title":"Acta Dermato-Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/TP.0b013e318180731e","article-title":"Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: A randomized study","volume":"86","author":"Wennberg","year":"2008","journal-title":"Transplantation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.jid.5700098","article-title":"Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: Results of a randomized-controlled trial","volume":"126","author":"Kennedy","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bjd.15884","article-title":"Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: A randomized intraindividual controlled trial","volume":"178","author":"Halldin","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1524-4725.2009.01384.x","article-title":"Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy","volume":"36","author":"Willey","year":"2010","journal-title":"Dermatol. Surg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jdv.15852","article-title":"Photodynamic therapy for the prevention and treatment of actinic keratosis\/squamous cell carcinoma in solid organ transplant recipients: A systematic review and meta-analysis","volume":"34","author":"Liew","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/jdv.16125","article-title":"Daylight photodynamic therapy for prevention of new actinic keratosis and keratinocyte carcinomas in organ transplants. A cryotherapy-controlled randomized clinical trial","volume":"34","author":"Bernad","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaad.2022.04.013","article-title":"Focused update: Guidelines of care for the management of actinic keratosis","volume":"87","author":"Eisen","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"19912s5","DOI":"10.36849\/JDD.19912","article-title":"Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes","volume":"24","author":"Jeong","year":"2025","journal-title":"J. Drugs Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdin.2024.07.001","article-title":"Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study","volume":"17","author":"Bhatia","year":"2024","journal-title":"JAAD Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"338","DOI":"10.36849\/JDD.8264","article-title":"Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)","volume":"23","author":"Schlesinger","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"AB79","DOI":"10.1016\/j.jaad.2024.07.321","article-title":"52742 Real-world patient\/clinician-reported outcomes of tirbanibulin for actinic keratosis: Indirect comparison between KLIR and PROAK studies","volume":"91","author":"Schlesinger","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"100300","DOI":"10.1016\/j.ejcskn.2025.100300","article-title":"Patient and physician-reported outcomes with tirbanibulin 1% ointment for actinic keratosis under conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)","volume":"3","author":"Gilaberte","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Balado-Sim\u00f3, P., Morgado-Carrasco, D., G\u00f3mez-Armayones, S., L\u00f3pez-Ferrer, A., Barco, D., Ferr\u00e1ndiz-Pulido, C., and Podlipnik, S. (2025). An Updated Review of Topical Tretinoin in Dermatology: From Acne and Photoaging to Skin Cancer. J. Clin. Med., 14.","DOI":"10.3390\/jcm14227958"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-030-46227-7_13","article-title":"The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers","volume":"1268","author":"Slominski","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s40200-025-01594-9","article-title":"Mapping the landscape of vitamin D in cancer studies: A systematic global investigation","volume":"24","author":"Faryabi","year":"2025","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2011.34.5967","article-title":"Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: Post hoc analyses of the women\u2019s health initiative randomized controlled trial","volume":"29","author":"Tang","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Park, S.M., Li, T., Wu, S., Li, W.Q., Qureshi, A.A., and Cho, E. (2016). Vitamin D intake and risk of skin cancer in US women and men. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160308"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1684\/ejd.2021.4137","article-title":"A 12-month follow-up split-scalp study comparing calcipotriol-assisted MAL-PDT with conventional MAL-PDT for the treatment of actinic keratosis: A randomized controlled trial","volume":"31","author":"Torezan","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104584","DOI":"10.1016\/j.phrs.2019.104584","article-title":"Advances on Natural Polyphenols as Anticancer Agents for Skin Cancer","volume":"151","author":"Sajadimajd","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1002\/fsn3.4555","article-title":"Effects of Resveratrol on Nonmelanoma Skin Cancer (NMSC): A Comprehensive Review","volume":"12","author":"Zamanian","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.72.10.4071","article-title":"Restoration of ultraviolet-induced unscheduled DNA synthesis of xeroderma pigmentosum cells by the concomitant treatment with bacteriophage T4 endonuclease V and HVJ (Sendai virus)","volume":"72","author":"Tanaka","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","first-page":"4227","article-title":"Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice","volume":"52","author":"Yarosh","year":"1992","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0781.1996.tb00188.x","article-title":"Enzyme therapy of xeroderma pigmentosum: Safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme","volume":"12","author":"Yarosh","year":"1996","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(00)04214-8","article-title":"Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study","volume":"357","author":"Yarosh","year":"2001","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Garcia-Mouronte, E., P\u00e9rez-Gonz\u00e1lez, L.A., Naharro-Rodriguez, J., and Fern\u00e1ndez Guarino, M. (2024). Understanding Active Photoprotection: DNA-Repair Enzymes and Antioxidants. Life, 14.","DOI":"10.3390\/life14070822"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Musielak, E., and Krajka-Ku\u017aniak, V. (2025). Enzymes DNA Repair in Skin Photoprotection: Strategies Counteracting Skin Cancer Development and Photoaging Strategies. Cosmetics, 12.","DOI":"10.3390\/cosmetics12040172"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10103-025-04327-9","article-title":"The evolving landscape of laser-based skin cancer prevention","volume":"40","author":"Wenande","year":"2025","journal-title":"Lasers Med. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e150972","DOI":"10.1172\/JCI150972","article-title":"Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia","volume":"131","author":"Spandau","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/onc.2009.440","article-title":"The IGF-1\/IGF-1R signaling axis in the skin: A new role for the dermis in aging-associated skin cancer","volume":"29","author":"Lewis","year":"2010","journal-title":"Oncogene"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/lsm.23175","article-title":"Single Ablative Fractional Resurfacing Laser Treatment for Forearm Actinic Keratoses: 6-Month Follow-Up Data from an Intrapatient Comparison Between Treated and Untreated Sites","volume":"52","author":"Chen","year":"2020","journal-title":"Lasers Surg. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e14402","DOI":"10.1111\/dth.14402","article-title":"The association of metformin use with keratinocyte carcinoma development in high-risk patients","volume":"33","author":"Misitzis","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2017.12.016","article-title":"Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes","volume":"78","author":"Tseng","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.36849\/JDD.8249","article-title":"Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study","volume":"23","author":"Haq","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Li, M., Li, X., Zhang, H., and Lu, Y. (2018). Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.01039"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1940-6207.CAPR-20-0376","article-title":"Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies","volume":"14","author":"Chang","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Chen, M., Liang, S., Shahid, A., Andresen, B.T., and Huang, Y. (2020). The \u03b2-blocker carvedilol prevented ultraviolet-mediated damage of murine epidermal cells and 3D human reconstructed skin. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030798"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1940-6207.CAPR-14-0193","article-title":"Prevention of skin carcinogenesis by the \u03b2-blocker carvedilol","volume":"8","author":"Chang","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/1940-6207.CAPR-20-0609","article-title":"Prevention of skin carcinogenesis by the non-b-blocking R-carvedilol enantiomer","volume":"14","author":"Liang","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"121302","DOI":"10.1016\/j.ijpharm.2021.121302","article-title":"Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption","volume":"611","author":"Yeung","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"E1802","DOI":"10.1503\/cmaj.201085","article-title":"The efficacy and safety of sunscreen use for the prevention of skin cancer","volume":"192","author":"Sander","year":"2020","journal-title":"Can. Med. Assoc. J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"122011","DOI":"10.1007\/s11356-023-30535-3","article-title":"Childhood sunburn and risk of melanoma and non-melanoma skin cancer: A Mendelian randomization study","volume":"30","author":"Li","year":"2023","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/phpp.12095","article-title":"Sunscreens\u2014What is the ideal testing model?","volume":"30","author":"Cole","year":"2014","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0190-9622(84)70088-0","article-title":"An animal model to determine sunscreen protectiveness against both vascular injury and epidermal cell damage","volume":"10","author":"Sambuco","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nm0597-510","article-title":"Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens","volume":"3","author":"Ananthaswamy","year":"1997","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1158\/1055-9965.EPI-06-0352","article-title":"Prolonged Prevention of Squamous Cell Carcinoma of the Skin by Regular Sunscreen Use","volume":"15","author":"Williams","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJM199310143291602","article-title":"Reduction of Solar Keratoses by Regular Sunscreen Use","volume":"329","author":"Thompson","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archderm.1995.01690140054008","article-title":"High Sun Protection Factor Sunscreens in the Suppression of Actinic Neoplasia","volume":"131","author":"Naylor","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","article-title":"Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: A 24 months, prospective, case-control study","volume":"161","author":"Ulrich","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","article-title":"Reduced melanoma after regular sunscreen use: Randomized trial follow-up","volume":"29","author":"Green","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/ijc.31997","article-title":"Challenges in assessing the sunscreen-melanoma association","volume":"144","author":"Rueegg","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1684\/ejd.2018.3251","article-title":"Use of sunscreen and risk of melanoma and non-melanoma skin cancer: A systematic review and meta-analysis","volume":"28","author":"Tavares","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2505400","DOI":"10.1080\/20450885.2025.2505400","article-title":"Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: Mechanisms affecting melanocytes","volume":"12","author":"Yusuf","year":"2025","journal-title":"Melanoma Manag."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00403-024-03551-7","article-title":"Update on skin cancer prevention modalities and screening protocols in solid organ transplant recipients: A scoping review","volume":"317","author":"Korzeniowski","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jdcr.2015.09.009","article-title":"Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients","volume":"1","author":"Breithaupt","year":"2015","journal-title":"JAAD Case Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/DSS.0000000000002072","article-title":"Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current Literature","volume":"45","author":"Herold","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cncr.31719","article-title":"Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials","volume":"125","author":"Jeter","year":"2018","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:17:25Z","timestamp":1769681845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":159,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030436"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030436","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}